Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
- Resource Type
- Article
- Authors
- Timmerman, John; Lavie, David; Johnson, Nathalie A.; Avigdor, Abraham; Borchmann, Peter; Andreadis, Charalambos; Bazargan, Ali; Gregory, Gareth P.; Keane, Colm; Tzoran, Inna; Vucinic, Vladan; Zinzani, Pier Luigi; Marceau West, Rachel; Pillai, Pallavi; Marinello, Patricia; Herrera, Alex F.
- Source
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p4440-4440, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020
Background: Programmed cell death protein 1 (PD-1) inhibitors are a standard of care for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), but better treatment options are needed for patients with anti-PD-1-refractory disease. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor with a role in regulating T-cell function. Dual blockade of PD-1 and LAG-3 has demonstrated antitumor activity in patients with advanced melanoma. Combination therapy with favezelimab (anti-LAG-3) and pembrolizumab (anti-PD-1) is currently being investigated in a phase 1/2 study (NCT03598608) in patients with R/R hematologic malignancies. Prior analyses showed that the combination had antitumor activity and manageable safety in patients with heavily pretreated anti-PD-1-refractory cHL (cohort 2). Updated results for this cohort are presented.